Yourgene Health PLC Result of AGM (7826Z)

TIDMYGEN

RNS Number : 7826Z

Yourgene Health PLC

22 September 2020

Yourgene Health plc

("Yourgene" or the "Company")

Result of AGM

Manchester, UK - 22 September 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces at the Annual General Meeting (AGM) held earlier today, all resolutions were duly passed.

The voting results will be made available on the 'Shareholder Communications' section of the Company's website

shortly:   https://www.yourgene-health.com/investors/key-documents/shareholder-communications 
 
Yourgene Health plc                                                 Tel: [phone] 
 Lyn Rees, Chief Executive Officer                             [e-mail] 
Barry Hextall, Chief Financial Officer 
Joanne Cross, Director of Marketing 
 
Cairn Financial Advisers LLP (NOMAD)                                Tel: [phone] 
Liam Murray / James Caithie / Ludovico 
 Lazzaretti 
 
N+1 Singer (Joint Corporate Broker)                                 Tel: [phone] 
Aubrey Powell / Tom Salvesen / George 
 Tzimas 
 
Stifel Nicolaus Europe Limited (Joint                               Tel: [phone] 
 Corporate Broker) 
Nicholas Moore / Matthew Blawat / Ben 
 Maddison 
 
 
Walbrook PR Ltd (Media and Investor      Tel: [phone] or [e-mail] 
 Relations) 
 Paul McManus / Lianne Cawthorne                             Mob: [phone] / Mob: 07584 
                                                                                     391 303 
 
 
 

About Yourgene Health plc

Yourgene is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.

Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, for reproductive health and molecular genetics. The Group's products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.

Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene is also extending its genetic testing offering into oncology.

Yourgene is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information, visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGKKBBDABKDDCB

(END) Dow Jones Newswires

September 22, 2020 12:14 ET (16:14 GMT)